•	Substitute for form 1449A/PTO		COMPLETE IF KNOWN
	INFORMATION DISCLOSURE	Application Number	10/797,257
	OTP E STATEMENT BY APPLICANT	Filing Date	March 10, 2004
	I	First Named Inventor	Billot et al.
g.	JUN 1 3 2005 PA	Group Art Unit	1614
E STATE OF THE STA	(use is many sheets as necessary)	Examiner Name	To be Assigned
	Sheet 1 of 1	Attorney Docket Number	MC080Y

			U.S. PA	TENT DOCUMENTS	
Examiner Initials*	Cite No.	U.S. Patent Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
				·	
			\dashv		
					•

				FOREIGN PA	TEN1	DOCUMENTS	
			Foreign Patent	Document			Date of Publication of
Examiner Initials*	Cite No.		Office	Number	Kind Code known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY
KN	I.	PCT	WO 04/063158		Al	F. Hoffmann-La Roche AG	07/29/2004
<u> </u>		-					
<u> </u>							
		_					
			1,				
Email			1/1/1/1/1	1/4			

Examiner Signature Date Considered 9/7/2005

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered.

					Laters and Luxuellant Olive: 0.2 DELYKLWENT OF COWWE	KLE
	Substitute for form 1449A/PTO)			COMPLETE IF KNOWN	
İ	INFORMATIO	N DISC	CLOSURE	Application Number	10/797,257	
K	ET CHEMENT I	D SZ A DI	DE ECANIT	Filing Date	March 10, 2004	
4	STATEMENT BY APPLICANT		LICANI	First Named Inventor	Billot et al.	
l mez	1 7 ° EI	•		Group Art Unit	1614	
\ I	(user) many since	eets as ne	cessary)	Examiner Name	To be Assigned	
. CSA	TATRICE 1	of	3	Attorney Docket Number	MC080Y	
\ I	(use many she	- 	ccessary)	Examiner Name	To be Assigned	

				U.S. PA	ATENT DOCUMENTS	
Exa Initi	miner als•	Cite No.	U.S. Patent Document Number	Kind Code ((f known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
KU		A.	6,344,477		Sharif	02/05/2002
	1	B.	5,889,052		Klimko et al.	03/30/1994
		C.	5,296,504		Stjernschantz et al.	06/06/1995
		D.	5,422,368		Stjernschantz et al.	06/06/1995
		E.	5,151,444		Ueno et al.	09/29/1992
		F.	5,352,708		Woodward et al.	10/04/1994
		G.	4,690,931		Wick et al.	09/01/1987
		Н.	6,043,275		Maruyama et al.	03/28/2000
		I.	US 2002/0065308		Cameron et al.	05/30/2002
لد	1	J.	6,747,037	BI	Old et al.	06/08/2004

				FOREI	GN PATENT	DOCUMENTS	
Examiner		Cite		Foreign Patent Documer	nt Kind	Name of Patentee or Applicant	Date of Publication of
lni	tials*	No.	Offic	e Number	Code (if known)	of Cited Document	Cited Document MM-DD-YYYY
	KN		K.	WO 02/24647	Al	Ono Pharmaceutical	03/28/2002
	7_		L.	WO 02/42268	A2	Pfizer Products Inc.	05/30/2002
			M.	EP 1114816	Al	Ono Pharmaceutical	07/11/2001
			N.	WO 01/46140	Al	Pfizer Products Inc.	06/28/2001
			О.	WO 03/105868	Al	Merck & Co. Inc.	12/24/2003
			P.	WO 03/105724		Merck & Co. Inc.	12/24/2003
			Q.	WO 03/105847	A1	Merck & Co. Inc.	12/24/2003
			R.	WO 02/060863	Al	Merck & Co. Inc.	08/08/2002
			S.	GB 1 524 818		Beecham Group Ltd.	11/29/1974
	$\sqrt{}$		T.	WQ 01/72268	A2	Merck & Co.	10/03/2002

Examiner Signature Date Considered 2005

^{*}Examiner: Initial if reference confidered, whether of not chation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form 1DS Form (IDS Folder), Merck & Co., Inc., 09/05/2003

Approved for use through 7/31/2006. CMB 0651-0031 SUBSTITUTE for PTO/SB/03A (08-03), Information Disclosure Statement by Applicant Parent and Trademark Office; U.S DEPARTMENT OF COMMERCE

s	ubstitute for form 1449A/PTO			С	OMPLETE IF KNOWN
1	NFORMATION	DIS	CLOSURE	Application Number	
٠ .	ישים אינות מודים אינויים אינויים	. A TO	DI ICANIT	Filing Date	
2	STATEMENT BY	Ar	PLICANI	First Named Inventor	
				Group Art Unit	
	(use as many sheets	as n	ecessary)	Examiner Name	
Sheet	2	of	3	Attorney Docket Number	

		U.S. PAT	TENT DOCUMENTS	
Cite No.	U.S. Patent Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
			····	
· · · · · ·				
		Cite No. Number	Cite No. Number Cite No. Number Code (if known)	Cite Number Kind Name of Patentee or Applicant Ocde Of Cited Document (if known)

				FORE	GN PATENT	DOCUMENTS	
		G:		Foreign Patent Documen	st .		Date of Publication of
Examiner Initials*		Cite No.	Office	Number	Kind Code (il known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY
K	<u>N</u>	U.		WO 94/13275	Al	Massachusettes Eye and Ear Infirmary	06/23/1994
]	V.		WO 01/70702	Al	Alcon Universal Ltd.	09/27/2001
		X.		WO 00/21542	Al	Merck & Co. Inc.	04/20/2000
		Y.		EP0855389	BI	Ono Pharmaceutical	01/26/1998
	Z.			WO 03/047417	A2	Merck & Co. Inc.	06/12/2003
		AA.		WO 03/047513	A2	Merck & Co. Inc.	06/12/2003
		BB.		EP 0 008 186	A1	Beecham Group Limited	07/30/1979
	V	CC.		WO 02/077168	A2	Merck & Co. Inc.	10/03/2002
L							

Examiner Signature Date Considered 9/1/2005

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

	Substitute for form 1449B/PTO				COMPLETE IF KNOWN				
	INFORMATION 1	DIS	CLOSURE	Application Number	10/797,257				
		. A T	DI ICANIT	Filing Date	March 10, 2004				
	STATEMENT BY	Ar	PLICANI	First Named Inventor	Billot et al.				
				Group Art Unit	1614				
	(use as many sheets	asr	necessary)	Examiner Name	To be Assigned				
Shee	1 3	of	3	Attorney Docket Number	MC080Y				

		NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.						
KX	DD.	P. Barraclough et al., "Heterocyclic Prostaglanding Analoughes. Part 4, Piperazine-2,5-diones, Pyrazolidine-3,5-diones, 1,2,4-Triazolidinediones, 1,3,4-Oxadiiazolidine-diones and 1,3,4-Thiadiazolidinediones", 1980, pp. 2096-2105, J.C.S. Perkin I.						
1	EE.	R. A. Schumer et al., "The Nerve of Glaucoma", 1994, pp. 37-44, Vol. 112, Arch Ophthalmol.						
	FF.	M. Weinreb et al., "Different Pattern of Alkaline Phosphatase, Osteopontin, and Osteocalcin Expression in Developing Rate Bone Visualized by in Situ Hybridization", 1990, Vol. 5, No. 8, J. of Bone and Mineral Research.						
	GG.	D. A. Dartt et al., "Localization of Nerves Adjacent to Goblet Cells in Rat Conjunctiva" 1994, pp. 993-1000, Vol. 14, Curr. Eye Res.						
	нн.	L. Dandona et al., "Selective Effects of Experimental Glaucoma on Axonal Transport by Retinal Ganglion Cells to the Dorsal Lateral Geniculate Nucleus", 1991, pp. 1593-1599, Vol. 32, No. 5, Investigative Ophthalmology & Visual Sciences.						
	II.	E. M. Ross, "Mechanisms of Drug Action and the Realtionship Between Drug Concentration and Effect", pp. 29-41, chapter 2, Goodman and Gilman's Pharmacological Basis of Therapeutics.						
	JJ.	I. K. Gipson et al., "Mucin Genes Expressed by the Ocular Surface Epithelium", 1997, pp. 81-98, Vol 16, No. 1, Progress in Retinal and Eye Research.						
	KK.	D. M. Shinar et al., "Expression of alphaV and Beta Integrin Subunits in Rat Osteoclasts in Situ", 1993, pp. 403-414, Vol. 8, No. 4, J. of Bone and Mineral Research.						
	LL.	M. A. Lemp et al., "Report of the National Eye Instittue/Industry Workshop on Clinical Trials in Dry Eyes", 1995, pp. 221-232, Vol. 21, No. 4, CLAO Journal.						
	мм.	M. Abramovitz et al., "The Utilization of Recombinant Prostanoid Receptors to Determine the Affinities and Selectivities of Prostaglandins and Related Analogs", 2000, pp. 285-293, Vol. 1483, Biochimica et Biophysica Acta.						
	NN.	P. Chomczynski et al., "Single-Step Mehtod of RNA Isolation by Acid Guanidinium Thiocyanante-Phenol-Chloroform Extraction", 1987, pp. 156-159, Vol. 162, Analytical Biochemistry.						
	00.	S.B. Rodan et al., "Growth Stimulation of Rat Calvaria Osteoblastic Cells by Acidic Fibroblast Growth Factor", 1987, pp.1917-1923, Vol. 121, No. 6, Endocrinology.						
	PP.	M. Abramovitz et al., "Human Prostanoid Receptors: Cloning and Characterization", 1995, pp. 499-504, Vol. 23, Advances in Prostaglandin Thromboxane, and Leukotriene Research.						
	QQ.	J. E. Larco et al., "Epithelioid and Fibroblastic Rat Kidney Cell Clones: Epidermal Growth Factor (EGF) Receptors and the Effect of Mouse Sarcoma Virus Transformation", 1978, pp.335-342, Vol. 94, J. Cell Physiol.						
V	RR.	T. J. Hodgkinson et al., "Practical Asymmetric Synthesis of Both Enantiomers of 6-(Hydroxymethyl) piperidin-2-one", pp. 1141-1144, Synthesis (1998)						

Examiner Signature	At	M	Mur	Date Considered	9/7/2005